Skip to content

Emma Hapke

9 papers in the library · 1,488 citations · publishing 2019-2025

Papers

Sort Most recent Most cited

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial

Pilot and Feasibility Studies October 28, 2025 Candice Richardson, Cindy Chan, Emily Macgregor et al. 1 citation

BACKGROUND: Individuals with advanced cancer often experience high levels of distress for which there are few standardized treatment approaches. Our multidisciplinary team has combined existing evidence-based approaches into Psilocybin-assisted Existential, Attachment, and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory...

An international Delphi consensus for reporting of setting in psychedelic clinical trials.

Nature Medicine June 3, 2025 Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman et al. 26 citations

Psychedelic substances exhibit complex interactions with the 'set and setting' of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables' known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based...

Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit Analysis.

Hastings Cent Rep July 1, 2024 Daniel Rosenbaum, Crystal Hare, Emma Hapke et al. 10 citations

Well-trained, competent therapists are crucial for safe and effective psychedelic-assisted therapy (PAT). The question whether PAT training programs should require aspiring therapists to undergo their own PAT-commonly referred to as "experiential training"-has received much attention within the field. In this article, we analyze the potential benefits of experiential training in PAT by applying...

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

Focus (American Psychiatric Publishing) July 1, 2023 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 97 citations

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...

Psilocybin mushrooms for psychological and existential distress

Canadian Family Physician November 1, 2022 Ryan Patchett-Marble, Sean O’sullivan, Sayali Tadwalkar et al. 13 citations

Psychedelic medicine is currently undergoing a renaissance, with interest in the medical use of these compounds exploding after decades of dormancy.[1][1] This has occurred primarily under the purview of medical researchers; however, recent legal precedents in Canada have allowed some access to

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.

Nature Medicine June 1, 2021 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 965 citations

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities

Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations

Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...

Psychedelic microdosing benefits and challenges: an empirical codebook

Harm Reduction Journal July 9, 2019 Thomas Anderson, Rotem Petranker, Adam Christopher et al. 130 citations

These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements...

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Psychopharmacology January 2, 2019 Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al. 171 citations

RationaleMicrodosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties,...